GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroOne Medical Technologies Corp (NAS:NMTC) » Definitions » ROE %

NeuroOne Medical Technologies (NeuroOne Medical Technologies) ROE % : -250.87% (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is NeuroOne Medical Technologies ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. NeuroOne Medical Technologies's annualized net income for the quarter that ended in Dec. 2023 was $-13.38 Mil. NeuroOne Medical Technologies's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $5.33 Mil. Therefore, NeuroOne Medical Technologies's annualized ROE % for the quarter that ended in Dec. 2023 was -250.87%.

The historical rank and industry rank for NeuroOne Medical Technologies's ROE % or its related term are showing as below:

NMTC' s ROE % Range Over the Past 10 Years
Min: -3294.69   Med: -190.21   Max: -123.78
Current: -238.08

During the past 13 years, NeuroOne Medical Technologies's highest ROE % was -123.78%. The lowest was -3,294.69%. And the median was -190.21%.

NMTC's ROE % is ranked worse than
95.16% of 805 companies
in the Medical Devices & Instruments industry
Industry Median: 0.25 vs NMTC: -238.08

NeuroOne Medical Technologies ROE % Historical Data

The historical data trend for NeuroOne Medical Technologies's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroOne Medical Technologies ROE % Chart

NeuroOne Medical Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -3,294.69 -230.81 -123.78 -149.61

NeuroOne Medical Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -77.99 -205.65 -293.55 -246.61 -250.87

Competitive Comparison of NeuroOne Medical Technologies's ROE %

For the Medical Devices subindustry, NeuroOne Medical Technologies's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroOne Medical Technologies's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's ROE % distribution charts can be found below:

* The bar in red indicates where NeuroOne Medical Technologies's ROE % falls into.



NeuroOne Medical Technologies ROE % Calculation

NeuroOne Medical Technologies's annualized ROE % for the fiscal year that ended in Sep. 2023 is calculated as

ROE %=Net Income (A: Sep. 2023 )/( (Total Stockholders Equity (A: Sep. 2022 )+Total Stockholders Equity (A: Sep. 2023 ))/ count )
=-11.859/( (9.604+6.249)/ 2 )
=-11.859/7.9265
=-149.61 %

NeuroOne Medical Technologies's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-13.38/( (6.249+4.418)/ 2 )
=-13.38/5.3335
=-250.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


NeuroOne Medical Technologies  (NAS:NMTC) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-13.38/5.3335
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-13.38 / 3.912)*(3.912 / 6.9595)*(6.9595 / 5.3335)
=Net Margin %*Asset Turnover*Equity Multiplier
=-342.02 %*0.5621*1.3049
=ROA %*Equity Multiplier
=-192.25 %*1.3049
=-250.87 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-13.38/5.3335
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-13.38 / -13.38) * (-13.38 / -13.56) * (-13.56 / 3.912) * (3.912 / 6.9595) * (6.9595 / 5.3335)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9867 * -346.63 % * 0.5621 * 1.3049
=-250.87 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


NeuroOne Medical Technologies ROE % Related Terms

Thank you for viewing the detailed overview of NeuroOne Medical Technologies's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroOne Medical Technologies (NeuroOne Medical Technologies) Business Description

Traded in Other Exchanges
N/A
Address
7599 Anagram Dr., Eden Prairie, MN, USA, 55344
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
Executives
Mark Christianson 10 percent owner, officer: VP, Business Dev and Marketing 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Ronald W. Mcclurg officer: Chief Financial Officer C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
David A Rosa director, officer: CEO and President 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Hijaz Haris officer: VP of Marketing C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
Morgan C. Frank 10 percent owner 2 CALLE NAIRN, UNIT 701, SAN JUAN PR 00907
Manchester Management Co Llc 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02110
Manchester Explorer, L.p. 10 percent owner MANCHESTER MANAGEMENT COMPANY, L.L.C, 3 WEST HILL PLACE, Boston ma 02114
James E Besser 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Manchester Management Pr, Llc 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Edward Andrle director C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DRIVE, EDEN PRAIRIE MN 55344
Wade Fredrickson 10 percent owner 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Steve Mertens officer: Chief Technology Officer 10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Scott Heuler officer: Vice President of Sales 10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Paul Buckman director 12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402
Suraj Kalia director 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347